BrainsWay Dirección

Dirección controles de criterios 2/4

El CEO de BrainsWay's es Hadar Levy , nombrado en Feb 2023, tiene una permanencia de 1.33 años. compensación anual total es $606.00K, compuesta por 55.3% salario y 44.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.12% de las acciones de la empresa, por valor de ₪472.41K. La antigüedad media del equipo directivo y de la junta directiva es de 10 años y 5 años, respectivamente.

Información clave

Hadar Levy

Chief Executive Officer (CEO)

US$606.0k

Compensación total

Porcentaje del salario del CEO	55.3%
Permanencia del CEO	1.3yrs
Participación del CEO	0.1%
Permanencia media de la dirección	11.4yrs
Promedio de permanencia en la Junta Directiva	5yrs

Actualizaciones recientes de la dirección

Recent updates

We Think BrainsWay (TLV:BWAY) Can Easily Afford To Drive Business Growth

May 03

BrainsWay Ltd.'s (TLV:BWAY) P/S Is Still On The Mark Following 26% Share Price Bounce

Dec 25

What Type Of Returns Would Brainsway's(TLV:BWAY) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 25

Brainsway Ltd. (TLV:BWAY): Is Breakeven Near?

Dec 26

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Hadar Levy en comparación con los beneficios de BrainsWay?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$2m
Dec 31 2023	US$606k	US$335k	-US$4m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$13m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$551k	US$412k	-US$13m
Sep 30 2022	n/a	n/a	-US$11m
Jun 30 2022	n/a	n/a	-US$8m
Mar 31 2022	n/a	n/a	-US$7m
Dec 31 2021	US$824k	US$443k	-US$6m
Sep 30 2021	n/a	n/a	-US$6m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	n/a	n/a	-US$5m
Dec 31 2020	US$502k	US$280k	-US$5m
Sep 30 2020	n/a	n/a	-US$7m
Jun 30 2020	n/a	n/a	-US$9m
Mar 31 2020	n/a	n/a	-US$12m
Dec 31 2019	US$590k	US$372k	-US$10m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$7m
Dec 31 2018	US$325k	US$155k	-US$6m

Compensación vs. Mercado: La compensación total de Hadar($USD606.00K) está por encima de la media de empresas de tamaño similar en el mercado IL ($USD437.11K).

Compensación vs. Ingresos: La compensación de Hadar ha aumentado mientras la empresa no es rentable.

CEO

Hadar Levy (50 yo)

1.3yrs

Permanencia

US$606,000

Compensación

Mr. Hadar Levy serves as Director of ReWalk Robotics Ltd. since August 03, 2022. He serves as Chief Executive Officer at BrainsWay Ltd.since February 13, 2023 and served as its Chief Operating Officer sin...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Hadar Levy	Chief Executive Officer	1.3yrs	US$606.00k	0.12% $ 471.6k
Avner Hagai	Founder & Director	18.4yrs	US$43.65k	6.22% $ 24.1m
Abraham Zangen	Co-Founder	no data	US$72.18k	2.81% $ 10.9m
Yiftach Roth	Founder & Chief Scientific Officer	18.1yrs	US$108.00k	3.28% $ 12.7m
Ido Marom	Chief Financial Officer	1.1yrs	sin datos	0% $ 0
Menachem Klein	VP, General Counsel & Corporate Secretary	11.4yrs	sin datos	sin datos

11.4yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BWAY es experimentado (10 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Avner Hagai	Founder & Director	18.4yrs	US$43.65k	6.22% $ 24.1m
Abraham Zangen	Co-Founder	5yrs	US$72.18k	2.81% $ 10.9m
Karen Sarid	Independent Director	6.5yrs	US$56.99k	0% $ 0
Yossi Ben Shalom	Independent Director	5.5yrs	US$42.12k	0.89% $ 3.4m
Amiram Boehm	Independent Chairman	1.4yrs	US$147.87k	0% $ 0
David Zacut	Co-Founder & Vice-Chairman	1.3yrs	US$35.79k	6.48% $ 25.1m
Eti Mitrany	Independent Director	8yrs	US$58.66k	0% $ 0
Mark George	Member of the Scientific Advisory Board	no data	sin datos	sin datos
David Feifel	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Mark Hallett	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Avner Lushi	Independent Director	4.4yrs	US$55.61k	0% $ 0
Zafiris Daskalakis	Member of the Scientific Advisory Board	2.7yrs	sin datos	sin datos

5.0yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de BWAY se considera experimentada (5 años de antigüedad promedio).

BrainsWay Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

BrainsWay Ltd., Annual General Meeting, Jun 17, 2024

Brainsway Ltd. Announces CFO Changes

BrainsWay Ltd., Annual General Meeting, Mar 20, 2023

BrainsWay Ltd. Appoints Ami Boehm as an Independent Director

BrainsWay Ltd. Promotes Hadar Levy to Senior Vice President and Chief Operating Officer

Brainsway Ltd., Annual General Meeting, Mar 04, 2021

Recent updates

BrainsWay Ltd. Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS for Depression for the Month of June 2024

BrainsWay Ltd. Receives Expanded FDA Labeling to Treat Late Life Depression

BrainsWay Ltd., Annual General Meeting, Jun 17, 2024

First quarter 2024 earnings released: EPS: US$0.003 (vs US$0.07 loss in 1Q 2023)

BrainsWay Ltd. Reiterates Revenue Guidance for the Year 2024

We Think BrainsWay (TLV:BWAY) Can Easily Afford To Drive Business Growth

BrainsWay Ltd. to Report Q1, 2024 Results on May 08, 2024

BrainsWay Ltd. Announces Publish Review Results Highlighting Potential of Deep Transcranial Magnetic Stimulation (Deep TMS™) as a Novel Therapeutic Approach for Parkinson's Disease

Brainsway Announces Positive Results in Late-Life Depression Post-Marketing Analysis

Full year 2023 earnings released: US$0.13 loss per share (vs US$0.41 loss in FY 2022)

New major risk - Revenue and earnings growth

Brainsway Ltd. Provides Earnings Guidance for Full Year 2024

BrainsWay Ltd. to Report Q4, 2023 Results on Mar 06, 2024

New minor risk - Market cap size

BrainsWay Ltd. Announces New Rotational Field Technology in Two New Feasibility Studies

BrainsWay Ltd.'s (TLV:BWAY) P/S Is Still On The Mark Following 26% Share Price Bounce

We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.15 loss in 3Q 2022)

BrainsWay Ltd. Announces Publishes the First Coverage Recommendations for Smoking Addiction Treatment Using TMS

BrainsWay Ltd. to Report Q3, 2023 Results on Nov 15, 2023

BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) for Depression

We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely

Forecast to breakeven in 2025

BrainsWay Ltd. to Report Q2, 2023 Results on Aug 09, 2023

We're Keeping An Eye On BrainsWay's (TLV:BWAY) Cash Burn Rate

Brainsway Ltd. Announces CFO Changes

No longer forecast to breakeven

BrainsWay Ltd. to Report Q1, 2023 Results on May 17, 2023

Full year 2022 earnings released: US$0.40 loss per share (vs US$0.21 loss in FY 2021)

BrainsWay Ltd., Annual General Meeting, Mar 20, 2023

BrainsWay Ltd. Appoints Ami Boehm as an Independent Director

BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™

Neuronetics Settles Litigation Against BrainsWay Ltd. and BrainsWay USA Inc

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.05 loss in 3Q 2021)

No longer forecast to breakeven

BrainsWay Ltd. to Report Q3, 2022 Results on Nov 16, 2022

BrainsWay Ltd Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS

BrainsWay Ltd. Receives New FDA Clearance for Treating Depression and Anxious Depression

We Think BrainsWay (TLV:BWAY) Can Afford To Drive Business Growth

Second quarter 2022 earnings released: US$0.07 loss per share (vs US$0.06 loss in 2Q 2021)

No longer forecast to breakeven

BrainsWay Ltd. to Report Q2, 2022 Results on Aug 10, 2022

BrainsWay Ltd. Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression

Brainsway Announces Positive OCD Coverage Policy from Blue Cross Blue Shield® (BCBS) Licensee Highmark BCBS for Deep TMS™

BrainsWay Ltd. Promotes Hadar Levy to Senior Vice President and Chief Operating Officer

BrainsWay (TLV:BWAY) Is In A Good Position To Deliver On Growth Plans

First quarter 2022 earnings released: US$0.06 loss per share (vs US$0.11 loss in 1Q 2021)

Neuronetics, Inc. Files Federal Lawsuit Against BrainsWay Ltd. for Misleading Psychiatrists and Patients

BrainsWay Ltd. to Present Expanded Post-Marketing Clinical Research for Major Depressive Disorder at Clinical TMS Society

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

BrainsWay Ltd. to Report Q4, 2021 Results on Mar 09, 2022

BrainsWay (TLV:BWAY) Is In A Strong Position To Grow Its Business

BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System

Forecast to breakeven in 2024

Brainsway Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects

Third quarter 2021 earnings released: US$0.05 loss per share (vs US$0.04 loss in 3Q 2020)

Forecast to breakeven in 2023

FDA Clears BrainsWay Deep TMS System for Decreasing Anxiety Symptoms in Depressed Patients

Second quarter 2021 earnings released: EPS US$0.06 (vs US$0.03 loss in 2Q 2020)

BrainsWay Announces Positive OCD Coverage Policy by Blue Cross Blue Shield Licensee HCSC

BrainsWay Announces First Draft Proposal for Obsessive-Compulsive Disorder Coverage

BrainsWay Ltd. Announces First of Its Kind Positive Coverage Policy by Centene for the Treatment of OCD Utilizing Deep TMS™

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.15 loss in 1Q 2020)

Brainsway Ltd. Receives FDA Clearance for Three-Minute Theta Burst Treatment Protocol for Major Depressive Disorder

Full year 2020 earnings released: US$0.24 loss per share (vs US$0.50 loss in FY 2019)

Full year 2020 earnings released: US$0.24 loss per share (vs US$0.50 loss in FY 2019)

Brainsway Ltd. to Report Q4, 2020 Results on Mar 24, 2021

What Is The Ownership Structure Like For Brainsway Ltd. (TLV:BWAY)?

Brainsway Ltd. has completed a Follow-on Equity Offering in the amount of $39.287 million.